Researchers from Yale Cancer Center and Hollings Cancer Center at the Medical University of South Carolina have published their clinical trial results in the American Journal of Preventive Medicine, showing the effectiveness of the drug varenicline in helping adults quit e-cigarettes. According to a report by Medical x Press on May 16th.
This is the first trial of the drug varenicline for smoking cessation using e-cigarettes in the United States, and the results appear quite optimistic. Researchers say it is worth conducting larger-scale research testing.
Lisa Fucito, Director of Tobacco Treatment Services at the Yale Cancer Center, stated that the trial was divided into two groups, a placebo group and a drug group, and the results showed significant differences between the two groups.
Our quit smoking rate has a 15% difference, with the medication group achieving a quit smoking rate of 45%.
Following the report on the trial of the smoking cessation drug cytisinicline, research findings on Varenicline have been published. These two drugs have similar effects, with Varenicline generics already on the market in the US, while cytisinicline has not yet been approved by the FDA for patient use. Varenicline, known by the brand name Chantix, has been FDA approved to help adults quit smoking. Despite the increasing number of e-cigarette users, there is currently no approved medication option to help them quit e-cigarettes.
This study demonstrates that the majority of e-cigarette users want to quit smoking, but it is not yet clear if products used to help quit traditional tobacco are equally effective for e-cigarettes.
We need more medication to treat the physical dependence caused by e-cigarettes. Symptoms are pronounced when trying to quit smoking, making withdrawal extremely uncomfortable. It cannot be dealt with solely by behavioral support.
It is worth noting that the study also included patients with a history of depression. This is important because Chantix has previously been linked to mental side effects and was therefore given a warning label. Although the warning was removed in 2016 after large-scale studies showed the drug to be safe, the negative perception of the medication still lingers among healthcare providers and the public.
Even though this drug is very safe and widely available, there are still some people who find it difficult to accept.
In this study, none of the participants experienced severe side effects; the majority only reported mild side effects such as nausea, insomnia, or nightmares. However, those who quit e-cigarettes did not switch to traditional tobacco.
The common concern is that former smokers who quit e-cigarettes may return to using traditional tobacco, but we have not found this to be the case.
On the other hand, the study results also revealed potential challenges: individuals who have never tried traditional tobacco and only used e-cigarettes may have a harder time quitting e-cigarettes, so this research still requires large-scale experimental support. However, Fuchito emphasized that it can increase confidence among medical providers when providing support to patients using varenicline to quit smoking.
We hope that people will return to this type of medication, and it may be difficult to quit e-cigarettes on their own, as the technology has promoted nicotine use to levels we have never seen before.
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
